Pharma News

New maximum prices for 814 programmed formulations were made effective with the NPPA drug price regulator setting the limit in sync with the new GST regime. These formulations include drugs used to treat cancer, HIV, diabetes and infections, among others.

Patients can continue to buy essential drugs in the MRP before the GST, ie not at the highest prices, until the new lots reach pharmacies and stockists, and reach the shelves.

Medical devices that are declared as "drugs", such as stents, valves, orthopedic implants, syringes and tools for operations, will now have to declare their retail maximum price (MRP) and other details including that of the manufacturer and the importer.

A recent survey on the state of label management in the pharmaceutical industry undertaken by NiceLabel in cooperation with Pharmaceutical Manufacturing revealsthe challenges facing pharmaceutical manufacturers as they try to produce accurate, compliant labels, and highlights the increasing importance of a single, integrated label management system.

Drug price regulator NPPA announced provisional maximum prices for 761 drugs, including anticancer drugs, HIV, diabetes and antibiotics, with a majority being reduced ahead of the GST implementation.

[adsense:336x280:8701650588]

Noncommunicable diseases (NCDs) kill 40 million people each year, says the World Health Organization (WHO). Noncommunicable diseases (NCDs), also known as chronic diseases, tend to be long-lasting and are the result of a combination of genetic, physiological, environmental and behavioral factors.

The Cabinet of the Union approved the signing of a memorandum of understanding for cooperation between India and Sri Lanka in traditional medical systems. The Memorandum of Understanding between the Ministry of AYUSH and the Ministry of Health, Nutrition and Indigenous Medicines of Sri Lanka will enhance bilateral cooperation in traditional medicine and homeopathy, an official statement said.

Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) and The National Institute of Virology (NIV), Pune, an institution of the Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare , New Delhi announced that they have signed an agreement for testing phytopharmaceutical, biologic and chemical entities developed by Sun Pharma against Zika, Chikungunya and Dengue viruses. Sun Pharma will provide drug molecules to NIV for testing against Zika, Chikungunya and Dengue in model systems.

ChromaDex Corp.an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has signed a new, exclusive patent license and research agreement with The Scripps Research Institute (TSRI), gaining access to groundbreaking, pre-clinical discoveries by Dr. Brunie Felding.  

pSivida Corp. a leader in the development of sustained release drug products and technologies,  announced the Company’s second Phase 3 trial of Durasert three-year treatment for posterior segment uveitis achieved the trial’s primary endpoint. The study involved 153 patients and the primary endpoint was prevention of recurrence of posterior uveitis at six months with patients continuing to be followed for 36 months.